Improvement of different vaccine delivery systems for cancer therapy

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Bolhassani, Azam ^a   Safaiyan, Shima ^a   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL PENETRATING PEPTIDE; DENDRIMER; DENDRITIC CELL VACCINE; DNA VACCINE; LIPOSOME; NANOPARTICLE; QUANTUM DOT; VIRUS VECTOR; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANTIGEN PRESENTING CELL; CANCER PREVENTION; CANCER THERAPY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE GUN IMMUNIZATION; GENE TRANSFER; HUMAN; LASER; NONHUMAN; REVIEW; ULTRASOUND; VIRUS LIKE AGENT; DENDRITIC CELL; GENE THERAPY; GENE VECTOR; IMMUNOLOGY; MUCOSAL IMMUNITY; NEOPLASM;

ANIMALIA;

CANCER VACCINES; CELL-PENETRATING PEPTIDES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNITY, MUCOSAL; LIPOSOMES; NANOPARTICLES; NEOPLASMS; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE;

EID: 78650949758     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-3     Document Type: Review

References (115)

1. Bodles-Brakhop AM, Draghia-Akli R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 2008, 7:1085-1101. 10.1586/14760584.7.7.1085, 18767956.
2. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Human Vaccines 2009, 5:671-689. 10.4161/hv.5.10.9370, 19684468.
3. Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: Preclinical studies and novel strategies. Advances in Cancer Research 2006, 115-137. 10.1016/S0065-230X(06)95004-0, 16860657.
4. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA Vaccines: Developing New Strategies against Cancer. Journal of Biomedicine and Biotechnology 2010, 1-16.
5. Schweighoffer T. Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations. Pathology & Oncology Research 1997, 3(3):164-176.
6. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Experimental and Molecular Medicine 2007, 39:679-689.
7. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Experimental and Molecular Medicine 2007, 39:679-689.
8. Zheng C, Juhls C, Oswald D, Sack F, Westfehling I, Wittig B, Babiuk LA, Hurk SDL. Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. Vaccine 2006, 24:4625-4629. 10.1016/j.vaccine.2005.08.046, 16154243.
9. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev 2008, 9:776-788.
10. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends in Molecular Medicine 2006, 12:216-222. 10.1016/j.molmed.2006.03.007, 16621717.
11. Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003, 31:207-216. 10.1016/S1046-2023(03)00135-X, 14511953.
12. Mikszta JA, Laurent PE. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev Vaccines 2008, 7:1329-1339. 10.1586/14760584.7.9.1329, 18980537.
13. Zaman M, Simerska P, Toth I. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response. Curr Drug Deliv 2010, 7(2):118-24. 10.2174/156720110791011846, 20158484.
14. Lai MD, Yen MC, Lin CM, Tu CF, Wang CC, Lin PS, Yang HJ, Lin CC. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genetic Vaccines and Therapy 2009, 7:1-13. 10.1186/1479-0556-7-2, 2639530, 19144125.
15. Pokorna D, Rubio I, Müller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008, 6:1-8. 10.1186/1479-0556-6-4, 2268933, 18179717.
16. Pokorna D, Polakova I, Kindlova M, Du skova M, Ludvikova V, Gabriel P, Kutinova L, Muller M, Smahel M. Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 2009, 27:3519-3529. 10.1016/j.vaccine.2009.03.073, 19464530.
17. Aravindaram K, Yang NS. Gene gun delivery systems for cancer vaccine approaches. Methods Mol Biol 2009, 542:167-178. full_text, 19565902.
18. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010, 1-27.
19. Liu L, Zhou X, Liu H, Xiang L, Yuan Z. CpG motif acts as a 'danger signal' and provides a T helper type 1-biased microenvironment for DNA vaccination. Immunology 2005, 115:223-230. 10.1111/j.1365-2567.2005.02150.x, 1782151, 15885128.
20. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector and syringe. Vaccine 2003, 21:4036-4042. 10.1016/S0264-410X(03)00275-5, 12922140.
21. Fechheimer M, Boylan JF, Parker S, Sisken JE, Patel GL, Zimmer SG. Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci USA 1987, 84:8463-8467. 10.1073/pnas.84.23.8463, 299564, 2446324.
22. Miller MW, Miller DL, Brayman AA. A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound Med Biol 1996, 22:1131-1154. 10.1016/S0301-5629(96)00089-0, 9123638.
23. Shen ZP, Brayman AA, Chen L, Miao CH. Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery. Gene Ther 2008, 15:1147-1155. 10.1038/gt.2008.51, 18385766.
24. Bekeredjian R, Kuecherer HF, Kroll RD, Katus HA, Hardt SE. Ultrasound-targeted microbubble destruction augments protein delivery into testes. Urology 2007, 69:386-389. 10.1016/j.urology.2006.12.004, 17320694.
25. Wallace M, Evans B, Woods S, Mogg R, Zhang L, Finnefrock AC, Rabussay D, Fons M, Mallee J, Mehrotra D, Schodel F, Musey L. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. The American Society of Gene Therapy 2009, 17:922-928.
26. Sundararajan R. Nano-electroporation: A first look. Methods in Molecular Biology 2008, 423:109-128. full_text, 18370193.
27. Hu H, Huang X, Tao L, Huang Y, Cui B, Wang H. Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Vaccine 2009, 27:1758-1763. 10.1016/j.vaccine.2009.01.021, 19186202.
28. Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005, 174:6292-6298.
29. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimized electroporation mediated DNA vaccination for treatment of prostate cancer. Genetic Vaccines and Therapy 2010, 8:1-13. 10.1186/1479-0556-8-1, 2829554, 20181099.
30. Seo SH, Jin HT, Park SH, Youn JI, Sung YC. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009, 27:5906-5912. 10.1016/j.vaccine.2009.07.033, 19651174.
31. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27:5450-5459. 10.1016/j.vaccine.2009.07.005, 2745985, 19622402.
32. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. Journal of Clinical Oncology 2008, 26(36):5896-5903. 2645111, 19029422.
33. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Molecular Therapy 2009, 17(4):585-592. 10.1038/mt.2009.5, 2835112, 19223870.
34. Kraft SD, Richter C, Zeil K, Baumann M, Beyreuther E, Bock S, Bussmann M, Cowan TE, Dammene Y, Enghardt W, Helbig U, Karsch L, Kluge T, Laschinsky L, Lessmann E, Metzkes J, Naumburger D, Sauerbrey R, Schürer M, Sobiella M, Woithe J, Schramm U, Pawelke J. Dose dependent biological damage of tumor cells by laser-accelerated proton beams. New Journal of Physics 2010, 12.
35. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000, 18:33-37. 10.1038/71889, 10625387.
36. Azevedo V, Levitus G, Miyoshi A, Cândido AL, Goes AM, Oliveira SC. Main features of DNA-based immunization vectors. Braz J Med Biol Res 1999, 32(2):147-153. 10.1590/S0100-879X1999000200002, 10347749.
37. Hilleman MR. Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol 2000, 19:79-90. 10.1016/S1386-6532(00)00132-3, 11091151.
38. Mills KHG. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunology Letters 2009, 122:108-111. 10.1016/j.imlet.2008.11.007, 19100777.
39. Marconi P, Argnani R, Epstein AL, Manservigi R. HSV as a Vector in Vaccine Development and Gene Therapy. Adv Exp Med Biol 2009, 655:118-144. full_text, 20047039.
40. Singh R, Kostarelos K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol 2009, 27:220-9. 10.1016/j.tibtech.2009.01.003, 19251331.
41. Basak SK, Kiertscher SM, Harui A, Roth MD. Modifying Adenoviral Vectors for Use as Gene-Based Cancer Vaccines. Viral Immunology 2004, 17(2):182-196. 10.1089/0882824041310603, 15279698.
42. Barzon L, Bonaguro R, Castagliuolo I, Chilosi M, Franchin E, Del Vecchio C, Giaretta I, Boscaro M, Palu G. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human IL-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 2003, 148:73-80. 10.1530/eje.0.1480073, 12534360.
43. El-Aneed A. An overview of current delivery systems in cancer gene therapy. Journal of Controlled Release 2004, 94:1-14. 10.1016/j.jconrel.2003.09.013, 14684267.
44. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of IL-2 and IL-12 genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002, 20:1862-1869. 10.1016/S0264-410X(02)00032-4, 11906776.
45. Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther 2010, 10:56-76. 10.2174/156652310790945566, 20156188.
46. Kim-Schulze S, Kaufman HL. Gene therapy for anti-tumor vaccination. Methods in Molecular Biology, Gene Therapy of Cancer 542:515-527. Walther W, Stein US.
47. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. Journal of Biomedicine and Biotechnology 2010, 1-13.
48. Narayani R. Polymeric delivery systems in biotechnology: a mini review. Trends Biomater Artif Organs 2007, 21:14-19.
49. Hellgren I, Gorman J, Sylven C. Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. J Drug Target 2004, 12:39-47. 10.1080/106118604200041403, 15203910.
50. Khatri K, Goyal AK, Vyas SP. Potential of nanocarriers in genetic immunization. Recent Pat Drug Deliv Formul 2008, 2:68-82. 10.2174/187221108783331348, 19075899.
51. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J 2007, 9:18-29.
52. Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 2005, 387:1-15. 10.1042/BJ20041053, 1134927, 15656784.
53. Narayani R. Polymeric delivery systems in biotechnology: A mini-Review. Trends Biomater Artif Organs 2007, 21:14-19.
54. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996, 35:1027-1036. 10.1021/bi952436a, 8547238.
55. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5:25-44. 10.1517/17425247.5.1.25, 18095927.
56. Myschik J, Rades T, Hook S. Advances in lipid-based subunit vaccine formulations. Current Immunology Reviews 2009, 5:42-48.
57. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. Journal of Biomedicine and Biotechnology 2010, 1-13.
58. Masotti A, Ortaggi G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev Med Chem 2009, 9:463-469. 10.2174/138955709787847976, 19356124.
59. Kircheis R, Schuller S, Brunner S, Ogris M, Heider KH, Zauner W, Wagner E. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med 1999, 1:111-120. 10.1002/(SICI)1521-2254(199903/04)1:2<111::AID-JGM22>3.0.CO;2-Y, 10738575.
60. Brown MD, Schatzlein A, Brownlie A, Jack V, Wang W, Tetley L, Gray AI, Uchegbu IF. Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug Chem 2000, 11:880-891. 10.1021/bc000052d, 11087338.
61. Moroson H. Polycation-treated tumor cells in vivo and in vitro. Cancer Research 1971, 31:373-380.
62. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009, 9:325-341. 10.1586/erm.09.15, 2701163, 19435455.
63. Baker JR. Dendrimer-based nanoparticles for cancer therapy. Nanotechnology for Hematology 2009, 708-719.
64. Chatterjee DK, Zhang Y. Multi-functional nanoparticles for cancer therapy. Science and Technology of Advanced Materials 2007, 8:131-133.
65. Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Patents on Drug Delivery & Formulation 2007, 1:37-51.
66. Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: application in vaccine delivery. Biochimica et biophysica Acta 2010, 1805:25-34.
67. Jarver P, Langel U. The use of cell-penetrating peptides as a tool for gene regulation. DDT 2004, 9:395-402.
68. Wagstaff KM, Jans DA. Protein transduction: cell penetrating peptides and their therapeutic applications. Current Medicinal Chemistry 2006, 13:1371-1387. 10.2174/092986706776872871, 16719783.
69. Zeng J, Wang S. Enhanced gene delivery to PC12 cells by a cationic polypeptide. Biomaterials 2005, 26:679-686. 10.1016/j.biomaterials.2004.03.006, 15282146.
70. Schirmbeck R, Riedl P, Zurbriggen R, Akira S, Reimann J. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells. The Journal of Immunology 2003, 171:5198-5207.
71. Riedl P, Reimann J, Schirmbeck R. Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med 2004, 82:144-152. 10.1007/s00109-003-0502-3, 14652667.
72. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005, 57:559-577. 10.1016/j.addr.2004.12.001, 15722164.
73. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997, 159:1666-1668.
74. Riedl P, Reimann J, Schirmbeck R. Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8+ T cell-stimulating immunogens. Methods Mol Med 2004, 127:159-169.
75. Giannouli C, Brulet JM, Gesché F, Rappaport J, Burny A, Leo O, Hallez S. Fusion of a tumor-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 2003, 23:3523-3532.
76. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. Journal of Controlled Release 2005, 109:299-316. 10.1016/j.jconrel.2005.09.036, 16298009.
77. Alexis F, Lo SL, Wang S. Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater 2006, 18:2174-2178.
78. Putnam D, Gentry CA, Pack DW, Langer R. Polymer based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci 2001, 98:1200-1205. 10.1073/pnas.031577698, 14732, 11158617.
79. Wang S. Tat peptide conjugates of low molecular weight polyethylenimine as effective non-viral gene delivery vectors. Mol Ther 2006, 13:76.
80. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. Comparison of two delivery systems efficiency by using polyethylenimine (PEI) for plasmid HPV16 E7 DNA transfection into COS-7 cells. Modarres J Med Sci 2008, 11:15-19.
81. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 2009, 16:196-204. 10.1080/10717540902757721, 19514980.
82. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Müller M. Enhanced immunogenicity of HPV16 E7 fusion proteins in DNA vaccination. Virology 2002, 294:47-59. 10.1006/viro.2001.1321, 11886264.
83. Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Therapy 2002, 9:489-496. 10.1038/sj.cgt.7700465, 12032659.
84. Roy P, Noad R. Virus-like particles as a vaccine delivery system. Human Vaccines 2008, 4:5-12.
85. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H. Immune response to human papillomavirus 16L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999, 81:881-888. 10.1002/(SICI)1097-0215(19990611)81:6<881::AID-IJC8>3.0.CO;2-T, 10362134.
86. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicitanti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998, 95:1800-1805. 10.1073/pnas.95.4.1800, 19193, 9465097.
87. Schiller J, Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001, 28:50-54.
88. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007, 7:79-89. 10.2174/156800907780006869, 17305480.
89. Krauzewicz N, Cox C, Soeda E, Clark B, Rayner S, Griffin BE. Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids. Gene Ther 2000, 7:1094-1102. 10.1038/sj.gt.3301219, 10918475.
90. Krauzewicz N, Stokrova J, Jenkins C, Elliott M, Higgins CF, Griffin BE. Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids. Gene Ther 2000, 7:2122-2131. 10.1038/sj.gt.3301322, 11223994.
91. Combita AL, Touze A, Bousarghin L, Sizaret PY, Munoz N, Coursaget P. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 2001, 204:183-188. 10.1111/j.1574-6968.2001.tb10883.x, 11682199.
92. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998, 26:1317-1323. 10.1093/nar/26.5.1317, 147398, 9469843.
93. Malboeuf CM, Simon DAL, Lee YEE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 2007, 25:3270-3276. 10.1016/j.vaccine.2007.01.067, 17293010.
94. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 2006, 80:759-768. 10.1128/JVI.80.2.759-768.2006, 1346844, 16378978.
95. Day PM, Baker CC, Lowy DR, Schiller JT. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci USA 2004, 101:14252-14257. 10.1073/pnas.0404229101, 521143, 15383670.
96. Kiesslich A, von Mikecz A, Hemmerich P. Cell cycle-dependent association of PML bodies with sites of active transcription in nuclei of mammalian cells. J Struct Biol 2002, 140:167-79. 10.1016/S1047-8477(02)00571-3, 12490165.
97. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J immunother 2009, 32:118-128. 10.1097/CJI.0b013e31818f13c4, 2717166, 19238010.
98. Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000, 30:848-857. 10.1002/1521-4141(200003)30:3<848::AID-IMMU848>3.0.CO;2-Q, 10741401.
99. Okada N, Saito T, Mori K, Masunaga Y, Fujii Y, Fujita J, Fujimoto K, Nakanishi T, Tanaka K, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochim Biophys Acta 2001, 1527:97-101.
100. Yoshikawa T, Okada N, Oda A, Matsuo K, Mukai Y, Yoshioka Y, Akagi T, Akashi M, Nakagawa S. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochem Biophys Res Commun 2008, 366:408-413. 10.1016/j.bbrc.2007.11.153, 18068668.
101. Wang L, Ikeda H, Ikuta Y, Schmitt M, Miyahara Y, Takahashi Y, Gu X, Nagata Y, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H. Bone marrow-derived dendritic cells incorporate and process hydrophobized poly-saccharide/oncoprotein complex as antigen presenting cells. Int J Oncol 1999, 14:695-701.
102. Kawamura K, Kadowaki N, Suzuki R, Udagawa S, Kasaoka S, Utoguchi N, Kitawaki T, Sugimoto N, Okada N, Maruyama K, Uchiyama T. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity. J Immunother 2006, 29:165-174. 10.1097/01.cji.0000190169.61416.f5, 16531817.
103. Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother 2004, 53:315-322. 10.1007/s00262-003-0461-0, 14685778.
104. Weiss JM, Allen C, Shivakumar R, Feller S, Li LH, Liu LN. Efficient responses in a murine renal tumor model by electroloading dendritic cells with whole-tumor lysate. J Immunother 2005, 28:542-550. 10.1097/01.cji.0000179437.95335.23, 16224271.
105. Suzuki R, Oda Y, Utoguchi N, Namai E, Taira Y, Okada N, Kadowaki N, Kodama T, Tachibana K, Maruyama K. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Journal of Controlled Release 2009, 133:198-205. 10.1016/j.jconrel.2008.10.015, 19000727.
106. Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 2010, 1-7.
107. Beaudette TT, Bachelder EM, Cohen JA, Obermeyer AC, Broaders KE, Fréchet JM, Kang ES, Mende I, Tseng WW, Davidson MG, Engleman EG. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm 2009, 6(4):1160-1169. 10.1021/mp900038e, 2731711, 19415922.
108. Moingeon P. Cancer vaccines. Vaccine 2001, 19:1305-1326. 10.1016/S0264-410X(00)00372-8, 11163653.
109. Coulie PG. Human tumor antigens recognized by T cells: new perspectives for anti-cancer vaccines?. Mol Med Today 1997, 3:261-268. 10.1016/S1357-4310(97)01049-6, 9211417.
110. Vocero-Akbani A, Lissy NA, Dowdy SF. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol 2000, 322:508-521. full_text, 10914043.
111. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994, 91:664-668. 10.1073/pnas.91.2.664, 43009, 8290579.
112. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev Vaccines 2010, 9:157-173. 10.1586/erv.09.160, 2837080, 20109027.
113. Chadwick S, Kriegel C, Amiji M. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 2009, 9:427-440. 10.1517/14712590902849224, 19344280.
114. Long CM, van Laarhoven HWM, Bulte JWM, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res 2009, 69:3180-3187. 10.1158/0008-5472.CAN-08-3691, 19276358.
115. Zhang H, Yee D, Wang C. Quantum Dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine 2008, 3:83-91. 10.2217/17435889.3.1.83, 18393668.